Daewon Pharmaceutical Co., Ltd. (KRX:003220)

Daewon Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	17,057	29,982	26,970	41,697	10,439
Short-Term Investments	29,051	47.71	20,036	13,123	81.5
Cash & Short-Term Investments	46,108	30,030	47,006	54,820	10,521
Cash Growth	53.54%	-36.11%	-14.26%	421.08%	-44.03%
Accounts Receivable	73,355	70,602	62,533	52,102	37,214
Other Receivables	4,317	2,580	3,906	2,363	4,473
Receivables	77,877	73,382	66,840	54,584	42,302
Inventory	113,166	105,078	91,847	69,690	63,798
Prepaid Expenses	716.31	488.39	426.61	353.29	182.28
Other Current Assets	1,486	314.56	1,165	929.46	474.22
Total Current Assets	239,353	209,293	207,284	180,377	117,276
Property, Plant & Equipment	208,378	160,092	158,912	166,674	157,252
Long-Term Investments	48,621	84,647	36,443	28,081	25,233
Goodwill	5,645	7,254	11,328	11,549	245.57
Other Intangible Assets	29,095	16,121	13,603	13,916	11,617
Long-Term Deferred Tax Assets	8,540	7,985	6,694	9,616	7,296
Long-Term Deferred Charges	20,057	18,096	15,142	14,977	11,809
Other Long-Term Assets	23,701	4,510	4,144	4,390	4,477
Total Assets	583,389	507,998	453,550	429,580	335,214
Accounts Payable	20,913	20,910	19,583	17,222	10,687
Accrued Expenses	5,686	4,885	4,352	3,741	3,220
Short-Term Debt	106,035	69,651	52,768	42,543	20,000
Current Portion of Long-Term Debt	12,917	39,803	9,284	8,822	1,500
Current Portion of Leases	1,800	1,123	1,344	362.95	948.28
Current Income Taxes Payable	4,403	2,485	4,913	4,367	1,244
Other Current Liabilities	49,023	43,833	35,903	25,019	18,417
Total Current Liabilities	200,776	182,690	128,146	102,076	56,017
Long-Term Debt	63,626	34,575	52,119	69,625	28,500
Long-Term Leases	2,863	897.72	961.42	2,616	1,530
Other Long-Term Liabilities	3,753	73.5	80	80	932.18
Total Liabilities	298,811	243,734	204,785	211,176	122,442
Common Stock	11,214	11,095	10,982	10,612	10,122
Additional Paid-In Capital	17,161	13,483	11,789	9,530	9,283
Retained Earnings	262,077	255,790	241,595	204,827	200,464
Treasury Stock	-15,063	-15,063	-15,063	-8,891	-8,806
Comprehensive Income & Other	-104.76	892.92	1,643	3,221	2,875
Total Common Equity	275,285	266,199	250,947	219,299	213,938
Minority Interest	9,294	-1,934	-2,182	-894.85	-1,166
Shareholders' Equity	284,578	264,264	248,765	218,404	212,772
Total Liabilities & Equity	583,389	507,998	453,550	429,580	335,214
Total Debt	187,241	146,050	116,476	123,968	52,478
Net Cash (Debt)	-141,133	-116,020	-69,471	-69,148	-41,957
Net Cash Per Share	-7300.20	-5530.07	-3175.72	-3258.76	-1965.93
Filing Date Shares Outstanding	21.41	21.2	20.97	20.6	20.21
Total Common Shares Outstanding	21.41	21.2	20.97	21.22	21.22
Working Capital	38,577	26,603	79,137	78,301	61,259
Book Value Per Share	12860.14	12558.89	11966.66	10335.27	10080.10
Tangible Book Value	240,544	242,823	226,017	193,833	202,075
Tangible Book Value Per Share	11237.23	11456.07	10777.82	9135.12	9521.15
Land	51,414	36,957	36,957	37,055	33,951
Buildings	122,341	107,803	107,710	79,558	89,713
Machinery	114,900	101,791	100,149	41,553	86,513
Construction In Progress	29,613	10,692	778.36	1,585	1,051

Source: S&P Global Market Intelligence. Standard template. Financial Sources.